Teva Pharma And Sanofi Report Duvakitug Maintained Efficacy Through 44 Weeks In Ulcerative Colitis And Crohn's Disease

Teva Pharmaceuticals and Sanofi reported positive results from the RELIEVE UCCD phase 2b long-term extension study, showing that the investigational drug duvakitug maintained high rates of clinical remission and response in patients with ulcerative colitis (UC) and Crohn's disease (CD) over 44 weeks. The study involved 130 patients and demonstrated that duvakitug was well tolerated, with safety consistent with previous findings. The data, which also included biomarker insights on inflammation and tissue remodeling, were presented at the United European Gastroenterology Week 2026.